AMO Pharma Shows Weakness In Myotonic Dystrophy
A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.
You may also be interested in...
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations.
A catastrophic late-stage clinical failure wipes 60% off the group’s value – and boosts a rival.